Amneal Pharmaceuticals announces the launch and US FDA approval of fluorometholone ophthalmic suspension, USP, 0.1%. The product received 180-day competitive generic therapy (CGT) exclusivity from the FDA, a status that applies to first-marketed generics of key medicines. The suspension is indicated for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.